Axial spondyloarthritis, Lancet, vol.390, pp.73-84, 2017. ,
The concept of spondyloarthritis: where are we now?, Best Pract Res Clin Rheumatol, vol.28, issue.5, pp.663-672, 2014. ,
Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis, Arthritis Res Ther, vol.18, p.196, 2016. ,
Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review, Ann Rheum Dis, vol.67, issue.7, pp.955-959, 2008. ,
Adalimumab in Patients with Active Noninfectious Uveitis, N Engl J Med, vol.375, issue.10, pp.932-943, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-02741384
Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial, Lancet, vol.388, issue.16, pp.31339-31342, 2016. ,
Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study, Ann Rheum Dis, vol.65, issue.12, pp.1631-1634, 2006. ,
Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept, Arthritis Rheum, vol.52, issue.8, pp.2447-2451, 2005. ,
Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register, Ann Rheum Dis, vol.76, issue.9, pp.1515-1521, 2017. ,
Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis, J Rheumatol, vol.41, issue.9, pp.1843-1848, 2014. ,
Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis, Arthritis Care Res (Hoboken), vol.68, issue.6, pp.838-844, 2016. ,
Treatment of seronegative spondyloarthropathyassociated uveitis with golimumab: retrospective case series, Clin Experiment Ophthalmol, vol.42, issue.4, pp.392-395, 2014. ,
Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab -The GO-EASY Study, J Rheumatol, vol.46, issue.2, pp.153-159, 2019. ,
Efficacy of anti-tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta-analysis, BMC Musculoskelet Disord, vol.16, issue.1, 2015. ,
Uveitis and spondyloarthropathies, Best Pract Res Clin Rheumatol, vol.31, issue.6, pp.846-862, 2017. ,
Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology, vol.120, issue.4, pp.777-787, 2013. ,
Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies, ACR Open Rheumatol, vol.2, issue.5, pp.294-299, 2020. ,
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection, Ann Rheum Dis, vol.68, issue.6, pp.777-783, 2009. ,
, Meta-Analysis Manual V3.pdf. Accessed, 2020.
Network Meta-Analysis using Frequentist Methods, 2015. ,
A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis, J Rheumatol, vol.37, issue.6, pp.1203-1210, 2010. ,
A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis, Arthritis & Rheumatology, vol.71, issue.7, pp.1101-1111, 2019. ,
A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis, Arthritis & Rheumatology, vol.67, issue.10, pp.2702-2712, 2015. ,
Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis, Arthritis Rheum, vol.60, issue.4, pp.946-954, 2009. ,
Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial, Ann Rheum Dis, vol.73, issue.3, pp.587-594, 2014. ,
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial, Arthritis Rheum, vol.54, issue.7, pp.2136-2146, 2006. ,
Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1), Ann Rheum Dis, vol.72, issue.6, pp.815-822, 2013. ,
Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial, Arthritis Rheum, vol.58, issue.11, pp.3402-3412, 2008. ,
Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT), Arthritis Rheum, vol.52, issue.2, pp.582-591, 2005. ,
Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the doubleblind, placebo-controlled INFAST study, Part 1, Ann Rheum Dis, vol.73, issue.1, pp.101-107, 2014. ,
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study, Ann Rheum Dis, vol.73, issue.1, pp.39-47, 2014. ,
Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study, Ann Rheum Dis, vol.64, issue.11, pp.1568-1575, 2005. ,
Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study, J Rheumatol, vol.45, issue.3, pp.341-348, 2018. ,
Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial, Rheumatology (Oxford), vol.53, issue.9, pp.1654-1663, 2014. ,
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial, Lancet, vol.359, issue.9313, pp.1187-1193, 2002. ,
A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis, Rheumatol Int, vol.30, issue.11, pp.1437-1440, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00562259
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebocontrolled trial, Lancet, vol.392, issue.18, pp.31946-31955, 2018. ,
Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis, Ann Rheum Dis, vol.69, issue.11, pp.1926-1928, 2010. ,
Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE), Ann Rheum Dis, vol.70, issue.5, pp.799-804, 2011. ,
Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis, Ann Rheum Dis, vol.65, issue.12, pp.1572-1577, 2006. ,
Evaluation of the nonsteroidal anti-inflammatory drugsparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study, Arthritis Res Ther, vol.16, issue.6, p.481, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01112377
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis, Ann Rheum Dis, vol.63, issue.12, pp.1594-1600, 2004. ,
Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial, Arthritis Rheum, vol.48, issue.11, pp.3230-3236, 2003. ,
Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis, Arthritis Rheum, vol.48, issue.6, pp.1667-1675, 2003. ,
Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial, Arthritis & Rheumatology, vol.66, issue.8, pp.2091-2102, 2014. ,
Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha, N Engl J Med, vol.346, issue.18, pp.1349-1356, 2002. ,
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors, Arthritis & Rheumatology, vol.71, issue.4, pp.599-611, 2019. ,
Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study, Rheumatol Ther, vol.5, issue.2, pp.447-462, 2018. ,
Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3, Arthritis Res Ther, vol.19, issue.1, p.285, 2017. ,
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis, N Engl J Med, vol.373, issue.26, pp.2534-2548, 2015. ,
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial, Lancet, vol.382, issue.9906, pp.1705-1713, 2013. ,
Secukinumab improves signs and symptoms of nonradiographic axial spondyloarthritis: primary results of a randomized controlled phase III study, Arthritis & Rheumatology, 2020. ,
Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial, Lancet, vol.395, pp.53-64, 2020. ,
Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate, Arch Ophthalmol, vol.121, issue.4, pp.437-440, 2003. ,
A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis, Arthritis Rheum, vol.53, issue.1, pp.18-23, 2005. ,
Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database, Curr Med Res Opin, vol.30, issue.12, pp.2515-2521, 2014. ,
, , 2013.
, GOL IV 2 mg/kg at wk 0, 4, 12 and then / 8 wk Placebo 28
, , 2015.
, IFX 5 mg/kg at wk 0, vol.2, p.24
, IFX 5 mg / kg at wk 0, vol.2, p.12
Infliximab 39 Placebo 37 IFX 3 mg / kg at wk 0, vol.2, p.6, 2010. ,
, IFX 5 mg / kg at wk 0, 2, 6, 14 and 22 Placebo 30
Infliximab 105 Placebo 52 IFX 5 mg / kg at wk 0, 2, 6, 12, vol.18, p.28, 2012. ,
Infliximab 34 Placebo 35 IFX 5 mg / kg at wk 0, vol.35, p.6, 2002. ,
, , 2002.
, SCK 150mg at wk 0,1,2,3 and then /4wk SCK 150mg at wk 0 and then /4wk Placebo 52
Secukinumab 24 Placebo 6 SCK IV 10 mg/kg /3wk Placebo 28, vol.51, 2013. ,
Secukinumab 394 Placebo 196 SCK IV 10 mg/kg /2wk 3x then 150 mg/4wk SCK IV 10 mg/kg /2wk 3x then 75 mg/4wk SCK 150 mg at wk 0,1,2,3 and then /4wk SCK 75 mg, vol.50, 2015. ,
, Risque de biais dans les ECR inclus, vol.2, p.33
, Annexe 3: Funnel plot